PDS Biotechnology has completed subject recruitment for stage 1 of its Phase II trial, evaluating the systemic administration of PDS01ADC.

Findings from a Phase I trial initiated by Dana-Farber Cancer Institute have showed NeoVaxMI's improved immune response in melanoma patients.

XyloCor has dosed the first subject in the multi-centre, randomised Phase IIb EXACT-2 trial to assess the gene therapy candidate, XC001.

A strategic framework has been devised with nine priority actions to enhance quality, accessibility, innovation and sustainability in trials.

UK & Ireland, experts provided insights on market trends within the clinical trial industry and advice on engagement strategies.

Pfizer and Astellas’ Xtandi (enzalutamide) has improved overall survival (OS) in patients with nmHSPC, but only as a combination therapy.

According to the World Health Organization, autism spectrum disorder (ASD) affects approximately 10% of children globally. ASD is theorised to be caused by a combination of genetic and environmental ...

The US FDA has approved Purespring Therapeutics’ IND application for PS-002, allowing the company to begin a Phase I/II trial.

US-based MAIA Biotechnology has dosed the first subject in Taiwan in the expansion phase of its multicentre THIO-101 Phase II trial.

Rhythm Pharmaceuticals is advancing its oral obesity drug bivamelagon to Phase III studies after it significantly reduced body mass index (BMI) in all three doses.

PulseSight Therapeutics has dosed the first subject in the Phase I trial of its first-in-class non-viral vectorised therapy, PST-611.

The companies are also running an open-label study to evaluate the long-term efficacy and safety of the psychedelic in ...